Week of October 15, 2012: Catalent Licenses NJIT Taste-Masking Technology; MicroConstants Completes FDA Inspection; and More - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Week of October 15, 2012: Catalent Licenses NJIT Taste-Masking Technology; MicroConstants Completes FDA Inspection; and More

ePT--the Electronic Newsletter of Pharmaceutical Technology

Catalent Pharma Solutions has taken an exclusive license to taste-masking technology developed by the New Jersey Institute of Technology. Under the terms of the license, Catalent will complete transfer of the technology into its cGMP facilities to support manufacture of dosage forms such as its Zydis fast-dissolve platform. Read More

On Sept. 20, 2012, an investigator from FDA visited MicroConstants’ San Diego, California, facility for a routine inspection to assess the CRO’s overall compliance with good laboratory practice regulations. During the visit, the investigator toured the facility and laboratory areas and reviewed several method validations, three sample analysis projects, and a pharmacokinetic analysis report. Upon completion of the inspection, the investigator reported zero findings, observations, or recommendations. Read More

Recipharm and Astimex Pharma have announced the formation of a collaboration agreement for the development and manufacture of a pharmaceutical product. The formulation development work will take place at the Recipharm Pharmaceutical Development site in Solna, Sweden. Astimex Pharma also has the opportunity to choose Recipharm as the future manufacturer for the product. Additionally, Astimex is in discussions with Recipharm for engagement to carry out other manufacturing and development contractual projects. Read More

A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers. Read More

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here